{"id":"https://genegraph.clinicalgenome.org/r/0e5010a2-4993-4fe5-8447-a5b5d6aadda5v1.9","type":"EvidenceStrengthAssertion","dc:description":"*FOLR1* was first reported in relation to autosomal recessive neurodegenerative syndrome due to cerebral folate transport deficiency in 2009 (Steinfeld et al., PMID: 19732866). *FOLR1* encodes a protein involved in folic acid binding. The disorder is characterized by progressive neurologic deterioration with developmental delay, intellectual disability, seizures, and movement disorders.\n\nFourteen variants (missense, nonsense, splice, inframe duplication) that have been reported in 17 probands in 10 publications (PMIDs: 19732866, 20857335, 21752681, 22586289, 24091540, 24556562, 25274592, 27066576, 27328863, 27743887) are included in this curation. More evidence is available in the literature, but the maximum score for genetic evidence (12 points) has been reached. The mechanism of pathogenicity is loss of function. Pathogenic variants result in loss of folate binding in patient cells (PMID: 19732866). \n\nIn summary, there is definitive evidence supporting the relationship between *FOLR1* and autosomal recessive neurodegenerative syndrome due to cerebral folate transport deficiency. This has been repeatedly demonstrated in both the research and clinical diagnostic settings, and has been upheld over time. This classification was approved by the ClinGen Intellectual Disability and Autism Gene Curation Expert Panel on October 20, 2017 (SOP Version 5). As of July 2022, this record underwent administrative updates to include an evidence summary text and update scoring to be consistent with SOP Version 9. No new evidence has been added.","dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/0e5010a2-4993-4fe5-8447-a5b5d6aadda5","GCISnapshot":"https://genegraph.clinicalgenome.org/r/22c12588-dc55-4e90-827a-d7a6349e38a9","calculatedEvidenceStrength":"Definitive","changes":[{"id":"cg:otherTextChange"},{"id":"cg:sopChange"},{"id":"cg:summaryChange"}],"contributions":[{"id":"https://genegraph.clinicalgenome.org/r/22c12588-dc55-4e90-827a-d7a6349e38a9_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10006","date":"2025-10-01T17:08:50.763Z","role":"Publisher"},{"id":"https://genegraph.clinicalgenome.org/r/22c12588-dc55-4e90-827a-d7a6349e38a9_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10006","date":"2017-10-20T10:00:00.000Z","role":"Approver"}],"curationReasons":["ErrorClarification"],"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/22c12588-dc55-4e90-827a-d7a6349e38a9_experimental_evidence_line","type":"EvidenceLine","specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/22c12588-dc55-4e90-827a-d7a6349e38a9_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f0da2f5a-5aab-4a60-ae65-de955014f210_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f0da2f5a-5aab-4a60-ae65-de955014f210","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19732866","rdfs:label":"Steinfeld P1","ageType":"AgeAtDiagnosis","ageUnit":"Years","ageValue":4,"allele":[{"id":"https://genegraph.clinicalgenome.org/r/440e93f1-15cd-4e8a-89a1-4f5b500e9142","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_016729.3(FOLR1):c.352C>T (p.Gln118Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA126338"}},{"id":"https://genegraph.clinicalgenome.org/r/d29116a7-98d8-4ef5-83b1-80edd33c7a91","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_016729.3(FOLR1):c.525C>A (p.Cys175Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA126340"}}],"ethnicity":{"id":"cg:NotHispanicOrLatino"},"firstTestingMethod":"Sanger sequencing","phenotypeFreeText":"Onset of symptoms at 2.5 years of age. Motor dysfunction, ataxia, developmental regression, and epileptic seizures. Supplementation with folinic acid led to clinical improvement.","sex":"Male","variant":[{"id":"https://genegraph.clinicalgenome.org/r/455ade81-5ed8-47f2-bca9-bd25c2506796_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19732866","allele":{"id":"https://genegraph.clinicalgenome.org/r/440e93f1-15cd-4e8a-89a1-4f5b500e9142"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}},{"id":"https://genegraph.clinicalgenome.org/r/793abbe9-b072-4d65-9bbe-15f64a4ca2dd_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19732866","allele":{"id":"https://genegraph.clinicalgenome.org/r/d29116a7-98d8-4ef5-83b1-80edd33c7a91"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}]},{"id":"https://genegraph.clinicalgenome.org/r/455ade81-5ed8-47f2-bca9-bd25c2506796","type":"EvidenceLine","dc:description":"Per ID/ASD GCEP, score capped at 2 points per individual","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/455ade81-5ed8-47f2-bca9-bd25c2506796_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/455ade81-5ed8-47f2-bca9-bd25c2506796_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Semiquantitative PCR analysis on patient cDNA showed no transcript. Binding studies in patient fibroblasts demonstrated a loss of folate binding.","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/793abbe9-b072-4d65-9bbe-15f64a4ca2dd","type":"EvidenceLine","dc:description":"Per ID/ASD GCEP, score capped at 2 points per individual","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/793abbe9-b072-4d65-9bbe-15f64a4ca2dd_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/793abbe9-b072-4d65-9bbe-15f64a4ca2dd_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Semiquantitative PCR analysis on patient cDNA showed no transcript. Binding studies in patient fibroblasts demonstrated a loss of folate binding.","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/8b5d382a-9489-4943-bb5f-6e6afb7d3f6f_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/8b5d382a-9489-4943-bb5f-6e6afb7d3f6f","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22586289","rdfs:label":"Grapp P2","allele":{"id":"https://genegraph.clinicalgenome.org/r/0316b55c-53eb-45e0-949e-507264cb7cc3","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_016729.3(FOLR1):c.195C>G (p.Cys65Trp)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA381731759"}},"firstTestingMethod":"Sanger sequencing","phenotypeFreeText":"Developmental delay, ataxia and cerebral hypotonia, seizures, microcephaly, ataxia, atethosis, regression, delayed myelination and cerebellar atrophy. Profound deficiency of CSF 5MTHF.","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/a4208765-d495-4752-bcb0-05bab3d57d91_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22586289","allele":{"id":"https://genegraph.clinicalgenome.org/r/0316b55c-53eb-45e0-949e-507264cb7cc3"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}},{"id":"https://genegraph.clinicalgenome.org/r/a4208765-d495-4752-bcb0-05bab3d57d91","type":"EvidenceLine","dc:description":"The missense variant was shown to result in loss of function","calculatedScore":1.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/a4208765-d495-4752-bcb0-05bab3d57d91_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/a4208765-d495-4752-bcb0-05bab3d57d91_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Transfection of mutant p.C65W in CHO-K1 cells showed only an expression level of 8% compared with the wild-type protein. Folic acid binding to transfected CHO-K1 cells showed loss of binding. The mutant was mistargeted to intracellular compartments and partly retained in the endoplasmic reticulum.","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":2}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/b71ff9d0-d50f-4008-b290-af3566f693fd_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/b71ff9d0-d50f-4008-b290-af3566f693fd","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27328863","rdfs:label":"Delmelle P1","ageType":"AgeAtReport","ageUnit":"Years","ageValue":3,"allele":{"id":"https://genegraph.clinicalgenome.org/r/14c40138-024c-4c31-acae-e91c58308413","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_016729.3(FOLR1):c.373C>T (p.Arg125Cys)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA6169177"}},"ethnicity":{"id":"cg:NotHispanicOrLatino"},"phenotypeFreeText":"Developmental delay, myoclonic epilepsy, regression, ataxia, hypotonia, choreic movements, and hypomyelination on brain MRI. CSF studies demonstrated diminished 5-methyltetrahydrofolate, with normal serum folic acid levels. Oral and intravenous folinic acid resulted in clinical improvement.","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/5610eb85-4eff-480a-b186-0be0f2201043_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27328863","allele":{"id":"https://genegraph.clinicalgenome.org/r/14c40138-024c-4c31-acae-e91c58308413"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}},{"id":"https://genegraph.clinicalgenome.org/r/5610eb85-4eff-480a-b186-0be0f2201043","type":"EvidenceLine","dc:description":"Score upgraded because of characteristic clinical and laboratory findings, and response to folinic acid therapy in the proband and her affected sister.","calculatedScore":0.2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/5610eb85-4eff-480a-b186-0be0f2201043_variant_evidence_item"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1.0}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1.0},{"id":"https://genegraph.clinicalgenome.org/r/4a081ebe-2607-4510-bb57-9a8b87207e88_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/4a081ebe-2607-4510-bb57-9a8b87207e88","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22586289","rdfs:label":"Grapp P1","allele":{"id":"https://genegraph.clinicalgenome.org/r/28c7ad29-dd71-44df-84f1-c0349b975d1a","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_016729.3(FOLR1):c.506G>A (p.Cys169Tyr)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA6169219"}},"ethnicity":{"id":"cg:NotHispanicOrLatino"},"firstTestingMethod":"Sanger sequencing","phenotypeFreeText":"Motor developmental delay, hypotonia, seizures, ataxia, atethosis, microcephaly, regression, hypomyelination and cerebral atrophy. Profound deficiency of CSF 5MTHF.","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/81f7351b-c04a-4296-9b20-ec8fcacd13bf_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22586289","allele":{"id":"https://genegraph.clinicalgenome.org/r/28c7ad29-dd71-44df-84f1-c0349b975d1a"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}},{"id":"https://genegraph.clinicalgenome.org/r/81f7351b-c04a-4296-9b20-ec8fcacd13bf","type":"EvidenceLine","dc:description":"The missense variant was shown to result in loss of function","calculatedScore":1.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/81f7351b-c04a-4296-9b20-ec8fcacd13bf_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/81f7351b-c04a-4296-9b20-ec8fcacd13bf_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Analysis of patient fibroblasts showed a weak faster migrating band and no expression of the 38 kDa fully maturated FRα form. Folic acid binding to transfected CHO-K1 cells showed loss of binding. The missense mutant was mistargeted to intracellular compartments and partly retained in the endoplasmic reticulum.","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":2}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/22c12588-dc55-4e90-827a-d7a6349e38a9_seg_el","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f3dd65f6-875b-4a9e-a916-a9d5298d2a1b_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27328863","rdfs:label":"Delmelle","family":{"id":"https://genegraph.clinicalgenome.org/r/f3dd65f6-875b-4a9e-a916-a9d5298d2a1b","type":"Family","rdfs:label":"Delmelle","member":{"id":"https://genegraph.clinicalgenome.org/r/b71ff9d0-d50f-4008-b290-af3566f693fd"}},"phenotypeFreeText":"regression in the second year of life, ataxia, and myoclonic epilepsy","phenotypePositiveAllelePositive":2,"proband":{"id":"https://genegraph.clinicalgenome.org/r/b71ff9d0-d50f-4008-b290-af3566f693fd"}},{"id":"https://genegraph.clinicalgenome.org/r/dceb784c-e238-421c-8837-b14e3bbaf424_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/24091540","rdfs:label":"Ohba","family":{"id":"https://genegraph.clinicalgenome.org/r/dceb784c-e238-421c-8837-b14e3bbaf424","type":"Family","rdfs:label":"Ohba","member":{"id":"https://genegraph.clinicalgenome.org/r/ffda27de-6b5b-4c87-a83d-470717232f24","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/24091540","rdfs:label":"Ohba P1","ageType":"AgeAtReport","ageUnit":"Years","ageValue":17,"allele":[{"id":"https://genegraph.clinicalgenome.org/r/4ba2a721-da2c-43d3-82f3-59aaae99972a","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_016729.3(FOLR1):c.466T>G (p.Trp156Gly)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA6169197"}},{"id":"https://genegraph.clinicalgenome.org/r/3af966d0-8929-4958-9227-10ac7369e1e0","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_016729.3(FOLR1):c.374G>T (p.Arg125Leu)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA381733043"}}],"firstTestingMethod":"Exome sequencing","phenotypeFreeText":"developmental delay, intellectual disability, limited speech, ataxia, seizures, hypotonia, cerebral white matter atrophy, calcification at subcortical white matter, extremely low concentration of 5-methyltetrahydrofolate in the cerebrospinal fluid","sex":"Male","variant":[{"id":"https://genegraph.clinicalgenome.org/r/61a54ead-e172-4fc6-a008-3551eebfc205_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/24091540","allele":{"id":"https://genegraph.clinicalgenome.org/r/3af966d0-8929-4958-9227-10ac7369e1e0"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}},{"id":"https://genegraph.clinicalgenome.org/r/71cdd5a8-a37d-4dd8-8451-169395f38e0d_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/24091540","allele":{"id":"https://genegraph.clinicalgenome.org/r/4ba2a721-da2c-43d3-82f3-59aaae99972a"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}]}},"phenotypeFreeText":"intellectual disability, ataxia, seizures, hypotonia","phenotypePositiveAllelePositive":2,"proband":{"id":"https://genegraph.clinicalgenome.org/r/ffda27de-6b5b-4c87-a83d-470717232f24"}},{"id":"https://genegraph.clinicalgenome.org/r/fabd9d80-ca95-4e50-bc8a-7db7c9ab0f15_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25274592","rdfs:label":"Al-Baradie","family":{"id":"https://genegraph.clinicalgenome.org/r/fabd9d80-ca95-4e50-bc8a-7db7c9ab0f15","type":"Family","rdfs:label":"Al-Baradie","member":{"id":"https://genegraph.clinicalgenome.org/r/d3f012ec-bd5c-4a15-8cd5-dccd0fe72c6c","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25274592","rdfs:label":"Al-Baradie P1","ageType":"AgeAtReport","ageUnit":"Years","ageValue":6,"allele":{"id":"https://genegraph.clinicalgenome.org/r/c971062d-09af-4e5a-9b0b-6ccc64f9e7c0","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_016729.3(FOLR1):c.398C>A (p.Pro133His)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA381733199"}},"ethnicity":{"id":"cg:NotHispanicOrLatino"},"firstTestingMethod":"Sanger sequencing","phenotypeFreeText":"Global developmental delay, intractable seizures, hypomyelination with cerebellar atrophy. Very low 5-methyltetrahydrofolate in CSF with no systemic folate deficiency. Responded clinically to folinic acid therapy.","previousTesting":true,"previousTestingDescription":"ALDH7A1 negative","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/d66854c6-84c8-4536-9da1-b8328c5fd73e_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25274592","allele":{"id":"https://genegraph.clinicalgenome.org/r/c971062d-09af-4e5a-9b0b-6ccc64f9e7c0"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}}},"phenotypeFreeText":"Global developmental delay and intractable seizures; responded clinically to folinic acid therapy.","phenotypePositiveAllelePositive":2,"proband":{"id":"https://genegraph.clinicalgenome.org/r/d3f012ec-bd5c-4a15-8cd5-dccd0fe72c6c"}}],"specifiedBy":"GeneValiditySegregationEvidenceCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/7787fe70-a331-4a1f-bdd8-6d70bec27426_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/7787fe70-a331-4a1f-bdd8-6d70bec27426","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/24556562","rdfs:label":"Toelle P1","ageType":"AgeAtReport","ageUnit":"Years","ageValue":5,"allele":{"id":"https://genegraph.clinicalgenome.org/r/933d21c1-1405-4190-919d-88de2cee81dc","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_016729.3(FOLR1):c.610C>T (p.Arg204Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA224405712"}},"firstTestingMethod":"Sanger sequencing","phenotypeFreeText":"Progressive ataxia with myoclonic jerks, regression, and myoclonic tonic spasms with drop attacks. Delayed myelination, cerebellar atrophy, and bilateral calcifications in the basal ganglia on cranial MRI.","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/6c2f1c4e-3bb0-45a9-8da2-d3e5fce6723a_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/24556562","allele":{"id":"https://genegraph.clinicalgenome.org/r/933d21c1-1405-4190-919d-88de2cee81dc"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}},{"id":"https://genegraph.clinicalgenome.org/r/6c2f1c4e-3bb0-45a9-8da2-d3e5fce6723a","type":"EvidenceLine","dc:description":"Per ID/ASD GCEP, score capped at 2 points per individual","calculatedScore":3.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/6c2f1c4e-3bb0-45a9-8da2-d3e5fce6723a_variant_evidence_item"}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":2}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/d3f012ec-bd5c-4a15-8cd5-dccd0fe72c6c_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d3f012ec-bd5c-4a15-8cd5-dccd0fe72c6c"},{"id":"https://genegraph.clinicalgenome.org/r/d66854c6-84c8-4536-9da1-b8328c5fd73e","type":"EvidenceLine","dc:description":"Score upgraded because of characteristic clinical and laboratory findings, and response to folinic acid therapy in the proband and his affected sister.","calculatedScore":0.2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d66854c6-84c8-4536-9da1-b8328c5fd73e_variant_evidence_item"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1.0}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1.0},{"id":"https://genegraph.clinicalgenome.org/r/42d10322-a80e-4ea4-b7d5-af79cf2a5cbc_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/42d10322-a80e-4ea4-b7d5-af79cf2a5cbc","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22586289","rdfs:label":"Grapp P5","allele":[{"id":"https://genegraph.clinicalgenome.org/r/28c7ad29-dd71-44df-84f1-c0349b975d1a"},{"id":"https://genegraph.clinicalgenome.org/r/a24df9e1-461d-4518-97a2-1df86db29764","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_016729.3(FOLR1):c.665A>G (p.Asn222Ser)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA6169242"}}],"ethnicity":{"id":"cg:NotHispanicOrLatino"},"firstTestingMethod":"Sanger sequencing","phenotypeFreeText":"Ataxia, seizures, regression, cerebellar atrophy, profound deficiency of CSF 5MTHF.","sex":"Female","variant":[{"id":"https://genegraph.clinicalgenome.org/r/9bd202da-2f60-4ef1-a673-bb4d87095147_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22586289","allele":{"id":"https://genegraph.clinicalgenome.org/r/28c7ad29-dd71-44df-84f1-c0349b975d1a"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}},{"id":"https://genegraph.clinicalgenome.org/r/7e2b74a8-fd30-480c-8bff-3587c0b50412_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22586289","allele":{"id":"https://genegraph.clinicalgenome.org/r/a24df9e1-461d-4518-97a2-1df86db29764"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}]},{"id":"https://genegraph.clinicalgenome.org/r/7e2b74a8-fd30-480c-8bff-3587c0b50412","type":"EvidenceLine","dc:description":"The missense variant was shown to result in loss of function","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/7e2b74a8-fd30-480c-8bff-3587c0b50412_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/7e2b74a8-fd30-480c-8bff-3587c0b50412_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Folic acid binding to CHO-K1 cells transfected with the mutant p. p.N222S showed severely decreased folic acid binding. The mutant was mistargeted to intracellular compartments and partly retained in the endoplasmic reticulum.","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/9bd202da-2f60-4ef1-a673-bb4d87095147","type":"EvidenceLine","dc:description":"The p.Cys169Tyr variant was shown to result in loss of function. This variant was reported in homozygous state in three unrelated Finish patients in this publication.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/9bd202da-2f60-4ef1-a673-bb4d87095147_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/9bd202da-2f60-4ef1-a673-bb4d87095147_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Folic acid binding to CHO-K1 cells transfected with the mutant p.C169Y showed loss of binding. The mutant was mistargeted to intracellular compartments and partly retained in the endoplasmic reticulum.","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/33741125-88a1-40cb-a27f-36f7b8654bcf_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/33741125-88a1-40cb-a27f-36f7b8654bcf","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19732866","rdfs:label":"Steinfeld P3","ageType":"AgeAtDiagnosis","ageUnit":"Years","ageValue":5,"allele":{"id":"https://genegraph.clinicalgenome.org/r/5f34ac03-c181-442a-92cd-917ad6faffe3","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"FOLR1, 18-BP DUP, NT130","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/16257"}},"ethnicity":{"id":"cg:NotHispanicOrLatino"},"firstTestingMethod":"Sanger sequencing","phenotypeFreeText":"Severely handicapped, intellectual disability, seizures","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/0c725e5f-0f71-4593-b3d2-a88f3449a84c_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19732866","allele":{"id":"https://genegraph.clinicalgenome.org/r/5f34ac03-c181-442a-92cd-917ad6faffe3"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}},{"id":"https://genegraph.clinicalgenome.org/r/0c725e5f-0f71-4593-b3d2-a88f3449a84c","type":"EvidenceLine","dc:description":"Per ID/ASD GCEP, score capped at 2 points per individual","calculatedScore":4,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/0c725e5f-0f71-4593-b3d2-a88f3449a84c_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/0c725e5f-0f71-4593-b3d2-a88f3449a84c_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Semiquantitative PCR analysis on patient cDNA showed an apparently normal transcript length. Binding studies in patient fibroblasts demonstrated a loss of folate binding.","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":2}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/3cae56be-03af-48ae-86c7-2c3101d6996a_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/3cae56be-03af-48ae-86c7-2c3101d6996a","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/21752681","rdfs:label":"Dill P1","ageType":"AgeAtReport","ageUnit":"Years","ageValue":8,"allele":{"id":"https://genegraph.clinicalgenome.org/r/933d21c1-1405-4190-919d-88de2cee81dc"},"firstTestingMethod":"Sanger sequencing","phenotypeFreeText":"Developmental delay, microtia, congenital deafness, hypotonia, dysphagia and ataxia in early childhood. At the age of 6 years he developed intractable epilepsy, and deteriorated clinically with episodes of respiratory arrest at the age of 8 years. Improved after treatment with folinic acid. This patient has a second recessive disorder, congenital deafness with labyrinthine aplasia, microtia and microdontia (LAMM syndrome), due to a homozygous variant in the FGF3 gene. All the reported individuals with this syndrome had normal cognitive and motor abilities.","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/c85d0db7-f21c-4f63-8414-50a3abe15107_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/21752681","allele":{"id":"https://genegraph.clinicalgenome.org/r/933d21c1-1405-4190-919d-88de2cee81dc"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}},{"id":"https://genegraph.clinicalgenome.org/r/c85d0db7-f21c-4f63-8414-50a3abe15107","type":"EvidenceLine","dc:description":"Per ID/ASD GCEP, score capped at 2 points per individual","calculatedScore":3.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c85d0db7-f21c-4f63-8414-50a3abe15107_variant_evidence_item"}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":2}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/7f6b0522-4dd7-46ae-82f3-8373ef9715df_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/7f6b0522-4dd7-46ae-82f3-8373ef9715df","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27066576","rdfs:label":"Ferreira P1","ageType":"AgeAtReport","ageUnit":"Years","ageValue":33,"allele":{"id":"https://genegraph.clinicalgenome.org/r/f8ef20df-a72d-4cf9-bd48-a4939fce69ab","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_016729.3(FOLR1):c.128A>G (p.His43Arg)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA381729800"}},"firstTestingMethod":"Exome sequencing","phenotypeFreeText":"Met her early developmental milestones until 22 months of age, when she developed myoclonic seizures, ataxia, and developmental regression. At 15 years of age, she had learned 75–100 words, but this decreased to only 12 words by age 30 years. By 7 years of age, she was wheelchair-dependent. There was a period of remission of her seizures from 11 to 18 years of age, but the generalized tonic-clonic seizures recurred in her 20s, particularly during sleep. CSF studies demonstrated diminished 5-methyltetrahydrofolate, consistent with cerebral folate deficiency. Oral folinic acid replacement resulted in clinical improvement.","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/6581c39f-9e23-4cd4-9ccf-7c3d0a1153db_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27066576","allele":{"id":"https://genegraph.clinicalgenome.org/r/f8ef20df-a72d-4cf9-bd48-a4939fce69ab"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}},{"id":"https://genegraph.clinicalgenome.org/r/6581c39f-9e23-4cd4-9ccf-7c3d0a1153db","type":"EvidenceLine","dc:description":"Score upgraded because of characteristic clinical and laboratory findings, and response to folinic acid therapy in the proband and her affected sister.","calculatedScore":0.2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/6581c39f-9e23-4cd4-9ccf-7c3d0a1153db_variant_evidence_item"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1.0}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1.0},{"id":"https://genegraph.clinicalgenome.org/r/ffda27de-6b5b-4c87-a83d-470717232f24_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ffda27de-6b5b-4c87-a83d-470717232f24"},{"id":"https://genegraph.clinicalgenome.org/r/71cdd5a8-a37d-4dd8-8451-169395f38e0d","type":"EvidenceLine","dc:description":"Score upgraded because of characteristic clinical and laboratory findings in the proband and his affected sister.","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/71cdd5a8-a37d-4dd8-8451-169395f38e0d_variant_evidence_item"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/61a54ead-e172-4fc6-a008-3551eebfc205","type":"EvidenceLine","dc:description":"Score upgraded because of characteristic clinical and laboratory findings in the proband and his affected sister. ","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/61a54ead-e172-4fc6-a008-3551eebfc205_variant_evidence_item"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1.0},{"id":"https://genegraph.clinicalgenome.org/r/bb71a989-bcb9-4fc4-ba9b-c741c441c8fe_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/bb71a989-bcb9-4fc4-ba9b-c741c441c8fe","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/20857335","rdfs:label":"Pérez-Dueñas P1","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":2,"allele":{"id":"https://genegraph.clinicalgenome.org/r/4f5b6779-b09f-450e-8f80-910b5dbac77b","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_016729.3(FOLR1):c.313T>C (p.Cys105Arg)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA381732511"}},"firstTestingMethod":"Sanger sequencing","phenotypeFreeText":"ataxic syndrome in the second year of life, followed by choreic movements and progressive myoclonic epilepsy. Diffuse abnormal signal of the cerebral white matter, cerebellar atrophy, and reduced peak of choline in spectroscopy. Profound deficiency of 5-methyltetrahydrofolate (5MTHF) in cerebrospinal fluid (CSF) with reduced CSF/plasma folate ratio, which is highly suggestive of defective brain folate-specific transport across the blood-CSF/brain barrier.","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/6c365162-2e54-4b29-b614-6fb4b9efa2f5_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/20857335","allele":{"id":"https://genegraph.clinicalgenome.org/r/4f5b6779-b09f-450e-8f80-910b5dbac77b"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}},{"id":"https://genegraph.clinicalgenome.org/r/6c365162-2e54-4b29-b614-6fb4b9efa2f5","type":"EvidenceLine","dc:description":"The missense variant was shown to result in loss of function","calculatedScore":1.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/6c365162-2e54-4b29-b614-6fb4b9efa2f5_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/6c365162-2e54-4b29-b614-6fb4b9efa2f5_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"The missense mutant p.C105R was shown to be mistargeted to intracellular compartments and partly retained in the endoplasmic reticulum, thus resulting in absent cellular binding of folic acid (Grapp et al., 2012, PMID: 22586289).","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":2}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/c8aa3f56-0ff0-46df-99f1-d550b693ba24_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c8aa3f56-0ff0-46df-99f1-d550b693ba24","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22586289","rdfs:label":"Grapp P7","allele":{"id":"https://genegraph.clinicalgenome.org/r/40ab5d34-3b46-4324-8295-96269a46832c","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_016729.3(FOLR1):c.357+1G>A","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA16042767"}},"ethnicity":{"id":"cg:NotHispanicOrLatino"},"firstTestingMethod":"Sanger sequencing","phenotypeFreeText":"Global developmental delay, ataxia, seizures, regression, autistic behavior, hypomyelination, cerebellar and cerebral atrophy, thin corpus callosum. Profound deficiency of CSF 5MTHF.","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/bdb67e65-b6b1-4053-85f1-e332a75c5b59_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22586289","allele":{"id":"https://genegraph.clinicalgenome.org/r/40ab5d34-3b46-4324-8295-96269a46832c"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}},{"id":"https://genegraph.clinicalgenome.org/r/bdb67e65-b6b1-4053-85f1-e332a75c5b59","type":"EvidenceLine","dc:description":"Per ID/ASD GCEP, score capped at 2 points per individual","calculatedScore":4,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/bdb67e65-b6b1-4053-85f1-e332a75c5b59_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/bdb67e65-b6b1-4053-85f1-e332a75c5b59_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"No expression of folate receptor alpha could be detected in patient fibroblasts.","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":2}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":2}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":12}],"evidenceStrength":"Definitive","sequence":11907,"specifiedBy":"GeneValidityCriteria9","strengthScore":12,"subject":{"id":"https://genegraph.clinicalgenome.org/r/YADqK6L3Mc8","type":"GeneValidityProposition","disease":"obo:MONDO_0013110","gene":"hgnc:3791","modeOfInheritance":"obo:HP_0000007"},"version":"1.9","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_22c12588-dc55-4e90-827a-d7a6349e38a9-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}